Equities

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Actions
  • Price (USD)46.90
  • Today's Change0.31 / 0.67%
  • Shares traded244.00
  • 1 Year change+21.42%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 16:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments577748740
Total Receivables, Net734028
Total Inventory342716
Prepaid expenses466872
Other current assets, total2.010.860
Total current assets732884857
Property, plant & equipment, net314286176
Goodwill, net444444
Intangibles, net166160131
Long term investments200155294
Note receivable - long term------
Other long term assets301319
Total assets1,4911,5451,522
LIABILITIES
Accounts payable424317
Accrued expenses209216156
Notes payable/short-term debt000
Current portion long-term debt/capital leases--0.180.57
Other current liabilities, total291.487.61
Total current liabilities280261181
Total long term debt000.41
Total debt00.180.98
Deferred income tax303233
Minority interest------
Other liabilities, total905900385
Total liabilities1,2161,193600
SHAREHOLDERS EQUITY
Common stock0.080.070.07
Additional paid-in capital3,6623,1402,997
Retained earnings (accumulated deficit)(3388)(2781)(2074)
Treasury stock - common(0.43)----
Unrealized gain (loss)1.25(5.73)(1.28)
Other equity, total(0.61)(0.85)(0.12)
Total equity275352923
Total liabilities & shareholders' equity1,4911,5451,522
Total common shares outstanding827069
Treasury shares - common primary issue0.0100
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.